TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company’s pipeline consists of a family of small molecule compounds called SMTPs (Stachybotrys Microspora Triprenyl Phenols) derived from a fungus. TMS’ lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company’s robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market.
IR Event
-
January 14, 2025
Announcement of FY02/2025 3Q Financial Results
- FY2025 (3Q)
-
Non-consolidated Financial Results for the Nine Months Ended November 30, 2024 [Japanese GAAP] (274KB)
- FY2025 (2Q)
-
Non-consolidated Financial Results for the Six Months Ended August 31, 2024 [Japanese GAAP] (309KB)
-
[Delayed]Presentation Material for the Six Months Ended August 31,2024 (1,954KB)
- FY2025 (1Q)
-
Non-consolidated Financial Results for the Three Months Ended May 31, 2024 [Japanese GAAP] (273KB)
- FY2024
-
Presentation Material for the Fiscal Year Ended February 29, 2024 (2,178KB)
-
Non-consolidated Financial Results for the Fiscal Year Ended February 29, 2024 [Japanese GAAP] (269KB)
- FY2024 (3Q)
-
[Delayed]Non-consolidated Financial Results for the Nine Months Ended November 30, 2023 [Japanese GAAP] (248KB)
[Note] Finantec Co., Ltd. is responsible for all matters concerning the retention and use of registered e-mail addresses. Registration data will be used solely for the distribution of IR STREET's IR information.